title: [Changes in the evaluation and treatment of benign prostatic hypertrophy].
abstract: The benign prostatic hyperplasia (BPH) is regarded as a widespread disease "potentially prevalent among the masses" owing to the increase of men's age. Morbidity rises from the age of 50, it runs up to 80-85% and causes symptoms in 40-60% that must be treated. Research and technical development have resulted important changes in treatment of BPH in the last years. Operation is not the only possible choice of treatment today. Treatments with drugs and instruments can also be successful in eliminating the symptoms in BPH.
authors.affiliation: Fövárosi Szent János Kórház-Rendelöintézet Urológiai-sebészeti osztály.
authors.forename: G
authors.initials: G
authors.lastname: Wabrosch
authors.forename: M
authors.initials: M
authors.lastname: Vanik
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002404:Catheterization; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011468:Prostatectomy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*
chemical_list: D000317:Adrenergic alpha-Antagonists